AJTMH ASTMH Job Mart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 56(6), 1997, pp. 621-626
Copyright © 1997 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baird, J. K.
Right arrow Articles by Hoffman, S. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baird, J. K.
Right arrow Articles by Hoffman, S. L.

Diagnosis of Resistance to Chloroquine by Plasmodium vivax: Timing of Recurrence and Whole Blood Chloroquine Levels

J. Kevin Baird, Budi Leksana, Sofyan Masbar, David J. Fryauff, M. Awaludin Sutanihardja, Suradi, F. Stephen Wignall AND Stephen L. Hoffman
U.S. Naval Medical Research Unit No. 2, Jakarta, Indonesia; Naval Medical Research Institute, Bethesda, Maryland

To develop criteria for the diagnosis of resistance to chloroquine using an in vivo test, we examined published records of early clinical trials of quinine and chloroquine against Plasmodium vivax. These data established the timing of relapse by tropical P. vivax relative to therapy by these drugs. The first relapse occurred 17 days after initiating and three days after terminating quinine therapy. The median day of relapse was day 23, and 59% of the patients had relapsed by day 30 (n = 333). In contrast, no relapse occurred until day 36 following chloroquine treatment (n = 256). Data from our laboratory may help explain this difference; among 91 Indonesian patients with malaria, the mean whole blood levels of chloroquine (CQ) and desethylchloroquine (DCQ) were 141 ng/ml (95% confidence interval = 115-167) on day 28 after initiating standard therapy (25 mg base/kg in three doses over a 48-hr period). This exceeds the estimated minimal effective concentration of chloroquine (100 ng/ml of whole blood). Thus, chloroquine lingering in the blood for at least 28 days after starting standard therapy was sufficient to eliminate or at least suppress chloroquine-sensitive tropical P. vivax. We conclude that a parasitemia by P. vivax recurring in the 28 days after full compliance to standard chloroquine therapy demonstrates resistance. If the recurrence appears before day 16, it is almost certainly a recrudescence and between days 17 and 28 it may be either a recrudescence or a relapse by chloroquine-resistant parasites. Recurrences beyond day 28 could be relapse by chloroquine-sensitive P. vivax.




This article has been cited by other articles:


Home page
 Am J Trop Med HygHome page
S. Pukrittayakamee, M. Imwong, P. Singhasivanon, K. Stepniewska, N. J. Day, and N. J. White
Effects of Different Antimalarial Drugs on Gametocyte Carriage in P. Vivax Malaria
Am J Trop Med Hyg, September 1, 2008; 79(3): 378 - 384.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
B. Russell, F. Chalfein, B. Prasetyorini, E. Kenangalem, K. Piera, R. Suwanarusk, A. Brockman, P. Prayoga, P. Sugiarto, Q. Cheng, et al.
Determinants of In Vitro Drug Susceptibility Testing of Plasmodium vivax
Antimicrob. Agents Chemother., March 1, 2008; 52(3): 1040 - 1045.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
R. N. Price, E. Tjitra, C. A. Guerra, S. Yeung, N. J. White, and N. M. Anstey
Vivax Malaria: Neglected and Not Benign
Am J Trop Med Hyg, December 1, 2007; 77(6_Suppl): 79 - 87.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
L. S. Vestergaard and P. Ringwald
Responding to the Challenge of Antimalarial Drug Resistance by Routine Monitoring to Update National Malaria Treatment Policies
Am J Trop Med Hyg, December 1, 2007; 77(6_Suppl): 153 - 159.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
J. Marfurt, I. Mueller, A. Sie, P. Maku, M. Goroti, J. C. Reeder, H.-P. Beck, and B. Genton
Low Efficacy of Amodiaquine or Chloroquine Plus Sulfadoxine-Pyrimethamine against Plasmodium falciparum and P. vivax Malaria in Papua New Guinea
Am J Trop Med Hyg, November 1, 2007; 77(5): 947 - 954.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
N. Tanomsing, M. Imwong, S. Pukrittayakamee, K. Chotivanich, S. Looareesuwan, M. Mayxay, C. Dolecek, T. T. Hien, V. E. do Rosario, A. P. Arez, et al.
Genetic Analysis of the Dihydrofolate Reductase-Thymidylate Synthase Gene from Geographically Diverse Isolates of Plasmodium malariae
Antimicrob. Agents Chemother., October 1, 2007; 51(10): 3523 - 3530.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
P. Druilhe, P. Brasseur, C. Blanc, and M. Makler
Improved Assessment of Plasmodium vivax Response to Antimalarial Drugs by a Colorimetric Double-Site Plasmodium Lactate Dehydrogenase Antigen Capture Enzyme-Linked Immunosorbent Assay
Antimicrob. Agents Chemother., June 1, 2007; 51(6): 2112 - 2116.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
J. P. Daily
Antimalarial drug therapy: the role of parasite biology and drug resistance.
J. Clin. Pharmacol., December 1, 2006; 46(12): 1487 - 1497.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Society of Tropical Medicine and Hygiene.